Effective biosimilar development pathway strategies and robust patient adherence improvement strategies are critical for market entry in cost-sensitive regions
In a six-month study, people taking the 14 mg daily dose lost around 4% of their body weight
A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace
ESC Heart Fail 11 , 837845 (2024)
In patients with T2D, model outcome was mostly affected by eGFR followed by age and the serum concentrations of the uremic toxin p -cresol 30 and D -threitol, also indicative of kidney function 39
Your healthcare provider can assess your specific situation, consider any underlying health conditions you may have and provide personalized recommendations